Latest Trials

2008

Trial HCV

VX-950-TiDP24-C210: A Study to Assess the Activity of Telaprevir on Hepatitis C Virus in Treatment naïve Patients Who Are Chronically Infected With Hepatitis C Genotype 4 Infection

Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels

Retreatment of Chronic Hepatitis C Non-Responders With Pegylated Interferon Alpha + Ribavirin + Pioglitazone

Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy

Vertex Hep C treatment enters late-stage trials

Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor

DIRECT is a randomized, open-label, phase III investigational research study that will evaluate the safety and efficacy of daily administration of subcutaneous interferon alfacon-1 plus ribavirin versus no treatment in HCV patients who have not responded to previous combination therapy with pegylated interferon alfa plus ribavirin.

Albuferon Dose in Ongoing Trials is Lowered Due to Safety Concerns

InterMune Announces Continuing Progress on HCV Protease Inhibitor ITMN-191 (R7227)

HCV  New Drug Pipeline

Continue reading "Trial to Test Potential HCV Triple Combination Therapy"

Roche responds to announcement of 'IDEAL' hepatitis C trial results

SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination Therapy -

IDEAL Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical trial results require careful interpretation

Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C -

2007

HCV-796 Dosing Discontinued

Romark Initiates Phase II Clinical Trial of Nitazoxanide (Alinia) for Chronic Hepatitis C -

Triphasic Decline of Hepatitis C Virus RNA during Interferon-based Antiviral Therapy

Idenix Suspends Testing of HCV Polymerase Inhibitor Valopicitabine (NM283)

HCV Drug Pipeline

Hepatitis C Clinical Trials

DDW 2007 Highlights: Part 2

DDW 2007 Highlights Part 1

2006

Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment For Patients

HCV Drug Pipeline

Fast Track for ACTILON

Novartis strengthens infectious disease portfolio by acquiring rights to Albuferon(TM), a hepatitis C interferon drug set to enter Phase III trials

From DDW JUNE 2006

Clinical Trials Preliminary Results

• ID# 1 – Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Patients With Chronic Hepatitis C Virus: Preliminary Results From a Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study
• ID# 4 – Valopicitabine (NM283), Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin (pegIFN/RBV) Retreatment in Hepatitis C Patients with Prior Non-Response to PegIFN/RBV: Week 24 Results
• Abstract S1057 – Stronger Baseline HCV-Specific Immunity Is Associated With A Higher Likelihood Of A Sustained Virological Response to Combination Antiviral Therapy Of Chronic Hepatitis C  (Updated May 21, 2006)
• Abstract S1058 – The impact of growth factors on Peg-Intron and Rebetol dose reduction in patients treated for genotype 1 chronic hepatitis C (Updated May 21, 2006)
• Abstract S1059 – Results of a Phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype-1 patients. (Updated May 25, 2006)
• Abstract S1060 – Comparison of Daily Consensus Interferon versus Peginterferon alfa 2a Extended Therapy of 72 Weeks for Peginterferon / Ribavirin Relapse Patients with Chronic Hepatitis C
• Abstract S1061 – Higher Susceptibility of Peginterferon alfa 2a versus Peginterferon alfa 2b Nonresponder Patients with Chronic Hepatitis C to Retreatment with Consensus Interferon Daily Dosing and Ribavirin
• Abstract S1062 – Early viral response to CPG 10101, a new investigational antiviral TLR9 agonist, in combination with pegylated interferon and/or ribavirin, in prior relapse HCV responders: preliminary report of a randomized Phase 1 study (Updated May 25, 2006)
• Abstract S1063 – The usefulness of sPECAM-1 and sVCAM-1 serum concentrations measurement in the assessment of fibrosis, inflammatory activity and antiviral therapy effectiveness in chronic hepatitis C

Open Clinical Trial of New PI SCH 503034 Plus PegIntron in HCV Patients Nonresponsive to Prior Treatment with Peginterferon Plus Ribavirin
(Feb 7 06)

Phase III Trial Shows Zadaxin Ineffective for Treatment of Hepatitis C among Nonresponders to Prior Treatment with Interferon

FDA Grants Fast Track Review to Schering-Plough's New Oral HCV Protease Inhibitor SCH 503034

Hepatitis C Clinical Trials 2006

2005

Hepatitis C Treatments in Current Clinical Development

(06/02/05)

HCV Drug NM283 Trial Fully Enrolled 

(06/02/05)

New HCV Drug Albuferon Starts Study in Genotype 1 Naives  

(06/02/05) 

How Ideal Is the IDEAL Trial?

June 2004

New Pegasys Study for HCV+ Untreated Patients with Genotype 1, High Weight & High Viral Load

June 30 2004
 

New Pegasys Trial to Enroll Hepatitis C Patients Not Helped by PEG-Intron

(repeat study)

Nation's Top Medical Centers Seek Participants for Largest Study Comparing Leading Hepatitis C Treatments
Thursday May 13, 8:59 am ET

InterMune Initiates Phase II Clinical Trial of Daily Infergen Plus Actimmune for the Treatment of Hepatitis C Nonresponders

Page Two

Human Genome Sciences Reports Interim Results of Phase 1/2 Clinical Trial of Albuferon(TM) in Patients Infected With Hepatitis C Virus

Clinical Trials: Hepatitis March 17 04

 Visit our Articles on Latest Trials (clicking here will take you to a new page)